Toxic effect of nano-zinc oxide

Hr, Espanani; Faghfoori, Zeinab; Izadpanah, M.R.; Vy, Babadi

doi:10.4149/bll_2015_119

Cited by 11 publications

(4 citation statements)

References 26 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dose level of ZnONPs (10 μg/kg per week, i.v., 4 weeks) was determined based on pilot trials, as there was no previous study performed on ZnONPs in vivo regarding anticancer potential. This dose level was much lower than the dose levels applied in acute or chronic studies for ZnONPs in rodents …”

Section: Methodsmentioning

confidence: 85%

Zinc oxide nanoparticles as a novel anticancer approach; in vitro and in vivo evidence

Hassan

Mansour

Abo-Youssef

et al. 2017

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Currently, the outcomes of conventional chemotherapeutic approaches are unsatisfactory. Clinical application of nanoparticles seems promising. We aim to evaluate the possible antitumor activity of zinc oxide nanoparticles (ZnONPs) as a chemotherapeutic approach in in vitro and in vivo experimental models. An in vitro study was performed on three different cell lines, namely human hepatocellular carcinoma (HEPG2), human prostate cancer (PC3), and none-small cell lung cancer (A549) cell lines. An in vivo study using diethylnitrosamine (DENA)-induced HCC in adult male Wistar rats was conducted to investigate the potential antitumor activity of ZnONPs in HCC and the possible underlying mechanisms. Hepatocellular carcinoma (HCC) was induced by oral administration of DENA given in drinking water (100 mg/L) for 8 weeks. Rats were allocated into four groups, namely a control group, an HCC control group receiving DENA alone, a ZnONPs (10 μg/kg per week, intravenous (i.v.) for 1 month) control group, and a ZnONPs treatment group (receiving ZnONPs + DENA). ZnONPs significantly reduced the elevated serum levels of HCC-related tumor markers alphafetoprotein and alpha-l-fucosidase and the apoptotic marker caspase-3 compared with the untreated HCC rats. In addition, treatment with ZnONPs significantly decreased the elevated levels of hepatocyte integrity and oxidative stress markers as compared with the untreated HCC control group. Furthermore, the histopathological study revealed anaplasia and fibrous degenerations which were significantly corrected by ZnONPs treatment. In conclusion, administration of ZnONPs exhibited a promising preclinical anticancer efficacy in HCC and could be considered as a novel strategy for the treatment HCC in clinical practices.

show abstract

Section: Methodsmentioning

confidence: 85%

Zinc oxide nanoparticles as a novel anticancer approach; in vitro and in vivo evidence

Hassan

Mansour

Abo-Youssef

et al. 2017

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

“…The marked decrease in lymph%, WBC, and MCHC may result from the blood leakage from the vessel walls caused by high doses of ZnO-NPs [37]. Espanani et al [38] reported similar hematological results for acute ZnO-NPs administration. However, Ben-Slama et al [31] results are inconsistent with ours; they found no hematological changes after ZnO-NPs ingestion.…”

Section: Discussionmentioning

confidence: 86%

Evaluation of acute oral toxicity of zinc oxide nanoparticles in rats

et al. 2021

View full text Add to dashboard Cite

Zinc oxide nanoparticles (ZnO-NPs) are widely used in the food and fertilizer industries. During our previous study, the bean fertilized by two doses (20 and 40 ppm) of ZnO-NPs with a particle size of 20 nm was investigated on rats. Therefore, this experiment was designed to evaluate effect of ZnO-NPs that were administrated orally to rats once a day at the doses 20 and 40 ppm. Hematological and biochemical parameters were quantified in addition to investigation of the deleterious effect on liver and kidney histopathological. In-vitro cytotoxicity of ZnO-NPs on the Vero cell line was also studied. Eighteen male Wistar rats were divided into three groups. Normal control (G1) was administered deionized water (1ml/rat). Groups G2 and G3 received 1ml/rat suspensions of 20 and 40 ppm ZnO-NPs, respectively. Hematology showed that the mean corpuscular hemoglobin concentration (MCHC) was lower in G2 and G3. White blood cell count was decreased in G2. G3 had an elevated hematocrit. In G2 and G3, plasma glucose decreased while uric acid and alkaline phosphatase activity increased. Plasma creatinine, aspartate aminotransferase, alanine aminotransferase, and creatine kinase were all elevated in G3, while albumin levels were decreased. Treatment with ZnO-NPs for 72 h resulted in no toxicity in Vero cells when compared to normal ZnO. Biochemical data were confirmed by histopathology. In conclusion, both doses of ZnO-NPs had minimal effects on the hematological parameters. While 40 ppm ZnO-NPs should be applied carefully due to their negative effects on liver and kidney functions.

show abstract

“…According toLiu et al (2015) zinc oxide nanoparticles can lead to increase in white and RBC, a decrease in lymphocyte count, and an increase in neutrophil count. By utilizing the same doses and routes administration of ZnO NPs but with various administration times up to 21 days,Espanani et al (2015) demonstrated in this period a decrease in the counts of platelet and lymphocyte with an increase in white cell count and no effect on the red cell count. Depending on the administered dose, sub-chronic use of zinc oxide…”

mentioning

confidence: 82%